GlassScriptPhysician profile
Heather B Cheek
NPI 1740235407
$7,394.39
in general payments reported to CMS, 2019-2025
59 companies · $1,194 in 2025
The $1,194 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,467 · 2022: $2,191 · 2023: $1,731 · 2024: $811 · 2025: $1,194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,736.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $812.03 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $412.16 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $382.03 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Seagen INC. | $359.16 | 2021-2023 | Adcetris, Tukysa, Padcev |
| Pfizer INC. | $348.88 | 2021-2025 | |
| Lilly USA, LLC | $334.21 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $326.74 | 2021-2025 | Calquence, Tagrisso |
| Amgen INC. | $319.31 | 2021-2023 | Kyprolis, Blincyto, Lumakras |
| Regeneron Healthcare Solutions, INC. | $315.90 | 2021-2025 | Libtayo |
| Genzyme Corporation | $306.72 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $269.71 | 2021-2024 | Alunbrig, Iclusig, Fruzaqla |
| Incyte Corporation | $207.13 | 2021-2024 | Jakafi, Pemazyre, Monjuvi |
| Astellas Pharma US INC | $192.20 | 2021-2024 | Xospata, Cresemba, Padcev |
| Janssen Biotech, INC. | $182.61 | 2021-2024 | Erleada |
| Kite Pharma, INC. | $168.08 | 2025 | Yescarta |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $162.42 | 2021-2025 | |
| Daiichi Sankyo INC. | $160.41 | 2022-2025 | Enhertu, Injectafer |
| Celgene Corporation | $139.69 | 2022-2024 | Pomalyst, Reblozyl |
| Glaxosmithkline, LLC. | $128.77 | 2021-2025 | Ojjaara, Shingrix |
| Rigel Pharmaceuticals, INC. | $127.69 | 2021-2023 | Rezlidhia, Tavalisse |
| Abbvie INC. | $117.99 | 2021-2025 | |
| Adc Therapeutics America, INC. | $96.79 | 2022-2025 | |
| Gilead Sciences, INC. | $88.16 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.61 | 2022-2023 | |
| Jazz Pharmaceuticals INC. | $78.21 | 2021-2024 | |
| Beone Medicines USA, INC. | $76.54 | 2025 | Brukinsa, Tevimbra |
| Alnylam Pharmaceuticals INC. | $75.79 | 2022-2023 | Givlaari |
| Genentech USA, INC. | $71.31 | 2022-2023 | Phesgo, Perjeta |
| Beigene USA, INC. | $67.62 | 2021-2024 | Brukinsa |
| Morphosys, US INC. | $66.37 | 2021-2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $65.37 | 2022-2023 | Fotivda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.99 | 2022-2024 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $53.67 | 2022-2023 | Onivyde, Somatuline Depot |
| Acrotech Biopharma INC. | $52.90 | 2022-2025 | Beleodaq |
| Tersera Therapeutics LLC | $49.55 | 2022 | |
| Taiho Oncology, INC. | $48.07 | 2022-2023 | |
| Mirati Therapeutics, INC. | $47.37 | 2023 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $46.03 | 2021-2023 | Imbruvica |
| Myovant Sciences INC. | $42.18 | 2021-2022 | |
| Puma Biotechnology, INC. | $39.44 | 2023-2024 | |
| Deciphera Pharmaceuticals INC. | $38.86 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $37.13 | 2021-2024 | Xpovio |
| Emd Serono, INC. | $31.09 | 2022-2023 | Bavencio |
| Geron Corporation | $27.73 | 2025 | Rytelo |
| Eusa Pharma (US) LLC | $27.06 | 2022 | |
| Forte Bio-Pharma LLC | $23.20 | 2023 | Prolate, Nalocet |
| Azurity Pharmaceuticals, INC. | $22.68 | 2025 | Danziten |
| Springworks Therapeutics, INC. | $21.95 | 2025 | Gomekli |
| Medtronic, INC. | $20.63 | 2022 | |
| Genmab U.S., INC. | $20.15 | 2023 | Epkinly |
| Stemline Therapeutics INC. | $19.82 | 2024 | Elzonris |
| Syndax Pharmaceuticals, INC. | $19.31 | 2025 | |
| Alexion Pharmaceuticals, INC. | $16.42 | 2021 | |
| Blue Earth Diagnostics | $15.84 | 2021 | |
| Exelixis INC. | $15.52 | 2022 | |
| Cti Biopharma Corp. | $14.14 | 2023 | Vonjo |
| Coherus Oncology, INC. | $13.79 | 2021 | |
| Mylan Institutional INC. | $12.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Cheek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.